CIK 0001745999 · Large accelerated filer
Beam Therapeutics Inc.
Sign in to watch- Ticker
- BEAM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-327-8775
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Former names
- Beam Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,193,310
- in 2 filings, $1.2M under 10b5-1 plans
Net −$1,193,310. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-31 | Simon Amy Chief Medical Officer | Grant or award | +31,750 | 109,114 | ||
| 2026-03-31 | Emany Sravan Kumar Chief Financial Officer | Grant or award | +31,750 | 105,456 | ||
| 2026-03-31 | Ciaramella Giuseppe President | Grant or award | +40,000 | 230,216 | ||
| 2026-03-31 | Evans John M. CEO | Option exercise 10b5-1 | +25,000 | $0.67 | $17K | 1,011,667 |
| 2026-03-31 | Evans John M. CEO | Sale 10b5-1 | −25,000 | $22.76 | $569K | 986,667 |
| 2026-03-31 | Evans John M. CEO | Grant or award 10b5-1 | +90,000 | 1,076,667 | ||
| 2026-03-31 | Evans John M. CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 18,672 | ||
| 2026-03-30 | Evans John M. CEO | Option exercise 10b5-1 | +25,000 | $0.67 | $17K | 1,011,667 |
| 2026-03-30 | Evans John M. CEO | Sale 10b5-1 | −25,000 | $22.37 | $559K | 986,667 |
| 2026-03-30 | Evans John M. CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 43,672 | ||
| 2026-02-24 | Ciaramella Giuseppe President | Option exercise 10b5-1 | +35,000 | $17.00 | $595K | 225,216 |
| 2026-02-24 | Ciaramella Giuseppe President | Sale 10b5-1 | −35,000 | $32.00 | $1.1M | 190,216 |
| 2026-02-24 | Ciaramella Giuseppe President | Option exercise · Stock Option (Right to Buy) 10b5-1 | −35,000 | 397,313 | ||
| 2026-01-31 | Ciaramella Giuseppe President | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-01-31 | Cavanagh Bethany J SVP, Finance and Treasurer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-01-31 | Emany Sravan Kumar Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +63,500 | 63,500 | ||
| 2026-01-31 | Bellon Christine Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-01-31 | Evans John M. CEO | Grant or award · Stock Option (Right to Buy) 10b5-1 | +180,000 | 180,000 | ||
| 2026-01-31 | Simon Amy Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +88,500 | 88,500 | ||
| 2026-01-30 | Evans John M. CEO | Option exercise 10b5-1 | +25,000 | $0.67 | $17K | 1,011,667 |
Page 3 of 32 · 630 trades